A 3D human skeletal muscle microtissue model of aging hallmarks
The abstract describes a 3D model built from human primary skeletal muscle cells in a muscle-derived scaffold; constructs from aged cells showed several aging-associated biological and functional phenotypes compared with young constructs. [1]
Automatic summary · not editorially reviewed
The key findings
The model uses human primary skeletal muscle cells embedded in a skeletal muscle-derived decellularized extracellular matrix scaffold. [1]
Aged and young constructs were compared across structural, molecular, mitochondrial, calcium-handling and contractile readouts. [1]
Compared with young constructs, aged constructs showed smaller myotubes, altered myogenic and inflammatory markers, mitochondrial alterations, delayed calcium responses and weakened contractile forces. [1]
The source at a glance
- Study type / format
- In vitro 3D cell-culture model study (abstract only)
- Population / context
- Human primary skeletal muscle cells from aged and young donors, used to build 3D constructs.
- Summary based on
- Study abstract
- Original publication
- September 11, 2026
Why a human muscle aging model was built
The abstract states that skeletal muscle is one of the largest organs and is central to mobility, metabolism and endocrine regulation. An aging global population makes understanding muscle aging important, but the authors say this is limited by a lack of in vitro models that reproduce biological and functional features of aged human muscle, and by differences between humans and animal models. They therefore present a 3D biomimetic aged muscle model using human primary skeletal muscle cells embedded in a skeletal muscle-derived decellularized extracellular matrix scaffold.
Supporting source [1]
Aged versus young constructs: measured differences
Constructs made from aged and young skeletal muscle cells were compared across structural, molecular, mitochondrial, calcium-handling and contractile readouts. Compared with young constructs, aged constructs showed several aging-associated phenotypes: smaller myotubes, altered expression of myogenic and inflammatory markers, mitochondrial alterations, delayed calcium responses and weakened contractile forces. These are described as phenotypes of the model, not as demonstrated causes of human aging or as proven benefits of any intervention.
Supporting source [1]
Proposed use and regulatory context
The authors say the platform allows biological and functional aspects of muscle aging to be assessed together and may serve as a translational tool to study mechanisms and screen therapies for age-associated muscle disorders. They link this to the FDA Modernization Act 2.0, which the abstract says recognizes in vitro human systems as alternatives to animal testing. This is a proposed research tool; the abstract does not report validation as a product, human lifespan outcomes or clinical results.
Supporting source [1]
How to interpret this
This explainer is based only on the abstract; the full text was not reviewed. The abstract reports no sample sizes, replication details or statistical results, and the model is presented as a proposed research platform, not a validated product or clinical therapy.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Yang S, Kong JS, Shin HY, Cho SC, Intisar A, Kim MY, Choi YJ, Lee YI, Cho DW, Kim MS. · europepmc.org · September 11, 2026